October 30, 2019
Chugai’s Hemlibra Approved for Hemophilia A Without Inhibitors in Taiwan
Hemlibra was approved for hemophilia A without inhibitors in Taiwan on 22 October 2019.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Chugai
October 30, 2019
EMA and FDA Accept Marketing Applications for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
NMOSD is a rare disease where repeated relapses may result in visual impairment and motor disability in the course of…
September 12, 2019
Chugai Presents Results from Second Positive Global Phase III Clinical Study of Satralizumab in NMOSD at ECTRIMS 2019
Following a positive study where satralizumab was added to baseline therapy, satralizumab monotherapy significantly reduced risk of relapse by 55%…